查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827208

复合药房市场按类型、应用、用例、分销管道和最终用户划分—2025-2032 年全球预测

Compounding Pharmacies Market by Type, Application, Use-Case, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年复合药房市场将成长 194.8 亿美元，复合年增长率为 6.99%。

主要市场统计数据
基准年2024年 113.4亿美元
预计2025年 120.9亿美元
预测年份：2032年 194.8亿美元
复合年增长率（%） 6.99%

关于个人化医疗、监管审查和製造业进步如何重塑复合药房在现代医疗保健中的作用的权威概述

复合药局产业处于个人化医疗、监管和专业製造之间的独特交汇点。临床医生和医疗保健系统日益寻求定製药物配方，以满足患者独特的需求，而这些需求无法透过现成的产品来满足。这种转变正在提升复合药局的作用，使其超越传统的利基服务，成为持续护理、儿科给药、客製化荷尔蒙替代和专业兽医护理的重要贡献者。同时，製剂科学、无菌处理和分析品管的进步正在扩展复合设施的技术能力，使其能够生产更复杂的无菌和眼科製剂。

随着法律规范不断发展，以平衡病患安全和个人化治疗的可及性，配药机构必须同时应对检测准备、产品检测预期和州级审批方面的差异。受全球原材料采购以及影响原材料供应和前置作业时间的突发中断的影响，供应链弹性已成为核心营运重点。因此，企业领导者必须整合临床、监管和营运策略，以在扩大产能的同时保持医疗保健的连续性。本介绍为后续的深入分析奠定了基础，包括结构性变化、关税影响、细分动态、区域影响和实用建议。

临床需求的整合、更严格的监管和製造创新将如何推动下一代复合药房生态系统

这些因素包括：临床对个人化製剂的需求日益增长，监管部门对产品品质和安全的要求日益提高，以及无菌和非无菌配製製程的技术改进。随着处方医生寻求针对小儿科、老年科和罕见疾病患者等人群的客製化浓度、替代剂型和联合治疗，临床需求正在不断增长。这种临床发展动能正在增强组合药物在皮肤科、荷尔蒙补充疗法、肿瘤支持治疗、疼痛管理和兽医应用领域的治疗相关性。

监管动态也在改变。他们优先考虑更严格的测试、增强的可追溯性以及更清晰的高风险无菌药品监管途径。这些监管期望要求对检验的无尘室环境、无菌保证通讯协定和强大的品管系统进行投资。同时，自动混合、封闭式配製设备和改进的防腐系统等製造技术正在实现更高的产量和稳定的产品品质。这些技术进步减少了差异性并支持更广泛的临床应用，但需要资本投入和熟练的人员。总而言之，这些转变增加了药房营运的复杂性，同时也为能够证明合规性、临床价值和供应可靠性的专业供应商创造了持久的机会。

评估 2025 年关税调整对复合药房供应连续性和製造经济性的连锁营运和采购影响

2025年的关税环境为从国际供应商采购原料、包装组件和专用生产设备的复合药局带来了重要的考量。关税将影响原料药、辅料、无菌组件、一次性耗材等的到岸成本，进而影响筹资策略和库存管理实务。为此，许多复方药房正在审查其供应商多元化，提高关键投入的安全库存水平，并评估近岸外包机会，以降低贸易政策波动带来的风险。

除了直接成本影响外，关税引发的波动还会波及供应商的前置作业时间和合约关係。采购团队正在重新协商商业条款，以确保可预测的供应窗口，并在主要资讯变得不那么可靠时考虑其他等级的包装树脂和聚合物。对一些组织而言，这些调整促使其资本配置转向在地化生产能力、提高自动化程度或与国内化学品製造商建立策略联盟。重要的是，服务于医院、诊所和零售药局的分销网络正在重新调整其物流布局，以在控制营运成本的同时保持服务水准。因此，供应链视觉性和情境规划日益重要，而强大的供应商资格认证和紧急框架正成为营运韧性的关键要素。

全面的細項分析揭示了配方复杂性、临床需求和分销管道的整合，从而决定了策略重点和营运重点

细分洞察阐明了临床需求、製造复杂性和商业管道之间的交集，揭示了优先发展能力和投资的必要性。从产品类型的角度来看，市场包含非无菌和无菌製剂。非无菌製剂包括胶囊、粉末、溶液/混悬液、糖浆和片剂等口服剂型，以及乳膏、凝胶、洗剂和软膏等外用剂型，这些都需要配方专业知识和稳定性测试。无菌製剂涵盖注射剂和眼用剂型，其中註射剂需要熟练的肌肉注射、静脉注射和皮下注射技能，而眼用剂型包括滴眼液和软膏，需要精确的防腐策略和颗粒控制。这些差异导致了不同的设施要求、品管测试和临床风险管理方法。

基于应用的细分进一步阐明了临床驱动因素。皮肤科专注于痤疮、湿疹和牛皮癣等疾病，通常需要外用製剂和活性浓度调整。荷尔蒙补充疗法涵盖雌激素、睪固酮和甲状腺製剂，需要精确的剂量和稳定性数据。同时，疼痛管理包括非阿片类药物和阿片类药物方案，需要独特的监管和转移考虑。动物用药品分为大型动物和小型动物製剂，剂量调整和特定物种的赋形剂耐受性会影响製剂选择。不同的用例（人类住院和门诊病人需求与大型和小型动物需求）决定了包装、预期保质期和分销流。分销管道包括直销和医院药房以及线上药房，每个管道都有不同的合规查核点、低温运输考虑因素和客户服务模式。最终用户涵盖学术和研究机构、诊所、家庭医疗保健、医院药房和零售药房，每个机构都有不同的文件、交付时间和可追溯性要求。整合这些细分领域，领导者能够将其技术能力与最具临床相关性和商业性永续的细分市场相结合。

监管、采购和临床需求方面的区域细微差别，要求配药药房在地理上协调其合规、采购和商业化策略

区域动态对监管预期、供应链设计和临床应用模式有着重大影响，因此需要製定针对特定地域的差异化策略。在美洲，联邦和州级法规结构对配药药房提出了一系列要求，这些要求必须满足。这种环境有利于那些投资于合规基础设施、州级许可安排以及与医院建立牢固伙伴关係的组织。美洲地区对个人化荷尔蒙疗法、儿科製剂和门诊无菌製剂的需求也十分巨大，这为专科服务线带来了商机。

欧洲、中东和非洲地区呈现多样化的监管和市场格局，包括国家医疗保健系统、不同的药典标准和不同的分销模式，需要采取适应性合规方法和符合文化背景的临床参与。在该地区的一些国家，严格的药物安全检测和以製造商为中心的期望提高了品质保证的标准，通常有利于与当地製造商建立合作伙伴关係和签订合约配药。亚太地区的特点是临床迅速采用个人化疗法、对当地製药製造业的投资不断增加以及监管协调工作不断发展。亚太地区的供应商正在提高其生产专用辅料和包装组件的能力，创造有竞争力的采购机会，同时也可能迫使当地公司达到国际品质标准。在所有地区，跨境监管资讯、供应商资格确认和物流规划对于保持一致的产品供应和支援临床连续性至关重要。

关键的竞争动态和能力差异将决定哪些药局供应商将在专业治疗领域获得信任、规模和临床伙伴关係关係

竞争格局主要由专业配药药房、医院配药部门以及提供配药和客製化剂量方案的合约开发和生产机构主导。领先的公司结合严格的品质系统、检验的无菌保证流程以及与临床网路的伙伴关係，以确保处方笺的投放。这些公司通常会投资强大的分析实验室、持续的员工培训计划和电子批次记录系统，以支援可追溯性和测试准备。除了内部能力之外，许多公司还利用与临床专家和学术中心的策略联盟来推动产品创新，检验利基配方，并仿单标示外或复杂用途配方建立临床证据。

差异化取决于营运规模、治疗专业知识的深度以及分销的敏捷性。能够快速交付且不影响品质的组织往往更容易与门诊诊所、家庭医疗保健提供者以及某些医院药房建立良好的合作关係。同时，能够进行小批量无菌生产并维持高合规标准的契约製造合作伙伴，对于需要肿瘤支持或特殊注射产品的医疗保健系统而言，具有吸引力。投资模式强调自动化以提高剂量准确性、环境监测的进步以及强大的供应链管治，以确保始终如一的投入品质。竞争策略越来越多地融入数位订购平台和临床咨询服务，以加深客户关係并提高处方和给药通讯协定的依从性。

为复合药房管理人员提供切实可行的优先行动，以加强合规性、供应弹性、临床伙伴关係和可扩展的製造能力

产业领导者应采取一系列优先行动来增强韧性、证明合规性并获得临床伙伴关係关係。首先，透过投资超越基本监管要求的品管系统来加强检验能力，包括全面的环境监测、检验的清洁程序和定期的第三方审核。其次，透过多样化供应商网络和对关键活性成分和无菌成分实施双重采购或近岸策略，减少贸易政策变化和物流中断的影响。第三，建立模组化设施能力，允许在非无菌和无菌配方之间灵活扩展，同时保持隔离和污染控制。第四，透过与处方医生和医院处方委员会建立合作关係来深化临床参与，以记录临床结果并加快联合疗法的接受度。第五，透过整合住院、门诊病人和兽医客户的数位订购、安全处方验证和分销服务来实现商业管道的现代化。

最后，制定前瞻性的人才策略，优先发展无菌药品生产专业知识、监管营运能力和供应链分析能力。这些倡议应遵循清晰的管治和可衡量的里程碑，以确保资本配置与最紧迫的营运缺口和对临床影响最大的领域一致。这些措施将使配药药房能够平衡监管合规性、临床相关性和营运效率。

调查方法，提供可操作且检验的策略指南

本分析整合了公开的监管指南、行业技术文献、对品质和营运负责人的专家访谈，以及在医院和营利性药局观察到的最佳实践。研究方法结合了对药典标准和州级法律规范的系统性回顾以及面对面咨询，以检验营运影响并探索实际的缓解策略。在适当情况下，我们也进行了比较设施评估，以获得关于无尘室分类、无菌检测方案和环境监测频率的建议。透过与物流负责人的访谈和物流绩效指标，对供应商和分销商进行了三角分析，以评估前置作业时间的波动性和应急计划实践。

透过对资讯来源的三角检验以及与领域专家的交叉检验，确保研究结果强调切实可行的指导，而非推测性情境。调查方法优先考虑可操作的讯息，重点在于可实施性、监管合规性和临床应用途径。研究的局限性包括州和国家法规的固有差异性以及贸易政策的动态性，因此本研究强调灵活策略和持续监测。整体而言，本调查方法基于实际营运情况和监管先例，提供了可靠的洞见。

策略整合强调品质第一的营运、供应弹性和临床协作的必要性，以确保长期生存能力和患者可及性

复方药房正处于关键的十字路口，个人化治疗的临床需求与日益严格的监管和复杂的供应链交织在一起。该行业的未来将青睐那些集严格的品质系统、灵活的生产平台和深度临床参与一体的供应商。不断变化的法规和关税趋势要求我们积极主动地实现供应商多元化、制定短期库存计划，并投资于高效的无菌处理能力。从自动配药系统到数位化处方检验，技术的采用可以提高准确性、吞吐量和合规性，但必须与持续的员工发展和管治相结合。

决策者应规划增量投资，以扩大无菌和眼科製剂产能，同时优先考虑能够立即提高合规性并显着提升服务可靠性的倡议。透过将明确的临床价值提案与营运韧性相结合，复合药房可以加强其在个人化医疗途径中的作用，并抓住人类和兽医领域的永续需求。总而言之，我们强调，数据驱动的有计划的投资和临床伙伴关係关係对于长期生存和维持患者获得重要的个人化治疗至关重要。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 在个人化肿瘤治疗中，越来越依赖具有先进安全措施的无菌配製
  • 根据个别患者荷尔蒙状况量身订製的荷尔蒙补充疗法配方解决方案的需求不断增长
  • 大规模实施机器人自动化和品管技术，以最大限度地减少配药药房的人为错误
  • 扩大远端医疗整合将促进远距处方笺履行和处方药送货上门
  • 兽医配药服务的成长，为外来动物和小动物照护提供专门的配方
  • 高调的复合设施检查已导致监管审查力度加大，合规性提高
  • 实施区块链追踪系统，实现原料和分销管道的端到端透明度
  • 加强医院药局与独立配药实验室的合作，有效解决药品短缺问题
  • 在药房工作流程中实施人工智慧驱动的处方检验和剂量优化平台，以提高准确性和吞吐量
  • 开发采用溶剂回收和可生物降解包装的绿色复合药房，以最大限度地减少对环境的影响

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章 复方药房市场（按类型）

  • 非无菌
    • 口服
      • 胶囊
      • 粉末
      • 溶液和悬浮液
      • 糖浆
      • 药片
    • 外用
      • 奶油
      • 凝胶
      • 洗剂
      • 软膏
  • 已灭菌
    • 注射
      • 肌肉注射
      • 静脉
      • 皮下
    • 眼科
      • 降低
      • 软膏

9. 复方药剂市场（依应用）

  • 皮肤科
    • 粉刺
    • 湿疹
    • 银屑病
  • 荷尔蒙补充疗法
    • 雌激素
    • 睪固酮
    • 甲状腺
  • 肿瘤学
  • 疼痛管理
    • 非阿片类药物
    • 阿片类药物
  • 兽医
    • 大型动物
    • 小动物

第 10 章复合药局市场（按用例）

  • 人类
    • 住院病人
    • 门诊
  • 兽医
    • 大型动物
    • 小动物

第 11 章 复方药局市场（依分销管道）

  • 直销
  • 医院药房
  • 网路药局

第 12 章 复方药房市场（按最终用户划分）

  • 学术研究机构
  • 诊所
  • 家庭医疗保健
  • 医院药房
  • 零售药局

第十三章 复方药房市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章复方药房市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按国家/地区分類的复合药房市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Fagron NV
    • Fresenius Kabi AG
    • PharMEDium（AmerisourceBergen Corporation）
    • B. Braun Medical Inc.
    • Ascend Clinical LLC
    • Medisca Inc.
    • Empower Pharmacy, Inc.
    • Wedgewood Village Pharmacy, LLC
    • Pencol Compounding Pharmacy Ltd.
    • Professional Compounding Centers of America, LLC
    • Diplomat Pharmacy, Inc.
Product Code: MRR-81515600A08D

The Compounding Pharmacies Market is projected to grow by USD 19.48 billion at a CAGR of 6.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.34 billion
Estimated Year [2025] USD 12.09 billion
Forecast Year [2032] USD 19.48 billion
CAGR (%) 6.99%

An authoritative overview of how personalized therapies, regulatory scrutiny, and manufacturing advances are reshaping compounding pharmacy roles in modern healthcare

The compounding pharmacy sector occupies a distinctive intersection between personalized medicine, regulatory oversight, and specialized manufacturing. Increasingly, clinicians and health systems seek customized formulations to meet unique patient needs that commercially available products cannot address. This shift has elevated the role of compounding pharmacies beyond traditional niche services toward essential contributors to therapeutic continuity, pediatric dosing, hormone replacement customization, and specialty veterinary care. In parallel, advances in formulation science, aseptic processing, and analytical quality controls have expanded the technical capabilities of compounding facilities, enabling more complex sterile products and ophthalmic preparations.

As regulatory frameworks evolve to balance patient safety with access to personalized therapies, compounding providers must simultaneously navigate inspection readiness, product testing expectations, and state-level licensure variations. Supply chain resilience has become a central operational priority, driven by global raw material sourcing and episodic disruptions that affect ingredient availability and lead times. Consequently, business leaders must integrate clinical, regulatory, and operational strategies to preserve continuity of care while scaling capabilities. This introduction establishes the context for deeper analysis of structural shifts, tariff impacts, segmentation dynamics, regional implications, and practical recommendations that follow.

How converging clinical demand, regulatory tightening, and manufacturing innovation are catalyzing a next-generation compounding pharmacy ecosystem

The compounding landscape is undergoing transformative shifts driven by three converging forces: rising clinical demand for personalized formulations, heightened regulatory expectations for product quality and safety, and technological improvements in sterile and non-sterile compounding processes. Clinical demand is broadening as prescribers seek custom concentrations, alternate dosage forms, and combination therapies for populations such as pediatrics, geriatrics, and patients with rare conditions. This clinical momentum is reinforcing the therapeutic relevance of compounded products in dermatology, hormone replacement therapy, oncology supportive care, pain management, and veterinary uses.

Regulatory dynamics are also shifting. Regulators are prioritizing more rigorous testing, enhanced traceability, and clearer pathways for oversight of high-risk sterile preparations. These regulatory expectations necessitate investments in validated cleanroom environments, sterility assurance protocols, and robust quality management systems. Concurrently, manufacturing technologies including automated mixing, closed-system compounding devices, and improved preservative systems are enabling higher throughput and more consistent product quality. These technological advances reduce variability and support broader clinical adoption; however, they require capital investment and skilled personnel. Taken together, these shifts increase the operational complexity of compounding practice but also create durable opportunities for specialized providers that can demonstrate compliance, clinical value, and supply reliability.

Assessing the cascading operational and procurement consequences of 2025 tariff shifts on supply continuity and manufacturing economics in compounding pharmacies

The tariff environment in 2025 has introduced material considerations for compounding pharmacies that source raw materials, packaging components, and specialized manufacturing equipment from international suppliers. Tariffs affect the landed cost of active pharmaceutical ingredients, excipients, sterile components, and single-use disposables, thereby influencing procurement strategies and inventory management practices. In response, many compounding facilities are reassessing supplier diversification, increasing safety stock levels for critical inputs, and evaluating nearshoring opportunities to mitigate exposure to trade policy volatility.

Beyond direct cost implications, tariff-induced shifts ripple through supplier lead times and contractual relationships. Procurement teams are renegotiating terms to secure predictable supply windows and exploring alternative resin and polymer grades for packaging when primary sources become less reliable. For some organizations, these adjustments prompt capital allocation toward localized manufacturing capabilities, incremental automation, or strategic partnerships with domestic chemical manufacturers. Importantly, the distribution networks that serve hospitals, clinics, and retail pharmacies are recalibrating their logistics footprints to maintain service levels while containing operating costs. The aggregate effect is a heightened emphasis on supply chain visibility and scenario planning, where robust supplier qualification and contingency frameworks become essential components of operational resilience.

Comprehensive segmentation analysis revealing where formulation complexity, clinical demand, and distribution channels converge to shape strategic priorities and operational focus

Segmentation insights illuminate where clinical need, manufacturing complexity, and commercial channels intersect, revealing prioritized operational capabilities and investment imperatives. From a product type perspective, the market encompasses both non-sterile and sterile preparations. Non-sterile offerings include oral forms such as capsules, powder, solutions and suspensions, syrups, and tablets, alongside topical forms like creams, gels, lotions, and ointments that demand formulation expertise and stability testing. Sterile solutions expand into injectables and ophthalmic products; injectables require proficiency in intramuscular, intravenous, and subcutaneous delivery methods while ophthalmic formulations include drops and ointments that demand precise preservative strategies and particulate control. These distinctions drive divergent facility requirements, quality control testing, and clinical risk management approaches.

Application-based segmentation further clarifies clinical drivers. Dermatology applications concentrate on conditions such as acne, eczema, and psoriasis, often requiring compounding of topical vehicles and active concentration adjustments. Hormone replacement therapy spans estrogen, testosterone, and thyroid preparations that call for accurate dosing and stability data. Oncology support services encompass adjunctive formulations for supportive care, while pain management includes both non-opioid and opioid regimens that carry unique regulatory and diversion-control considerations. Veterinary applications bifurcate into large animal and small animal needs, where dose scaling and species-specific excipient tolerability influence formulation choices. Use-case distinctions separate human inpatient and outpatient needs from veterinary large and small animal use, shaping packaging formats, shelf-life expectations, and distribution cadence. Distribution channels range from direct sales and hospital pharmacies to online pharmacies, each presenting different compliance checkpoints, cold chain considerations, and customer service models. End users extend across academic and research institutes, clinics, home healthcare, hospital pharmacies, and retail pharmacies, each imposing different documentation, turnaround, and traceability requirements. Synthesizing these segmentation layers enables leaders to align technical capabilities with the most clinically relevant and commercially sustainable niches.

Regional nuances in regulation, sourcing, and clinical demand that require geographically tailored compliance, sourcing, and commercialization strategies for compounding pharmacies

Regional dynamics exert meaningful influence on regulatory expectations, supply chain design, and clinical adoption patterns, necessitating geographically nuanced strategies. In the Americas, regulatory frameworks at both federal and state levels create a patchwork of requirements that compounding providers must navigate; this environment rewards organizations that invest in compliance infrastructure, state licensure coordination, and strong hospital partnerships. The Americas also host significant demand for personalized hormone therapies, pediatric formulations, and outpatient sterile preparations, driving opportunities for specialized service lines.

The Europe, Middle East & Africa region presents a diverse regulatory and market landscape where national health systems, varied pharmacopoeial standards, and differing distribution models require adaptable compliance approaches and culturally informed clinical engagement. In several countries within this region, stringent pharmacovigilance and manufacturer-centric expectations increase the bar for quality assurance, and local manufacturing partnerships or contract compounding arrangements often prove advantageous. The Asia-Pacific region is characterized by rapid clinical adoption of personalized therapies, growing investment in local pharmaceutical manufacturing, and evolving regulatory harmonization efforts. Suppliers in Asia-Pacific are increasingly capable of producing specialized excipients and packaging components, which can present both competitive sourcing opportunities and pressure on local players to match international quality standards. Across all regions, cross-border regulatory intelligence, supplier qualification, and logistical planning are essential to sustain consistent product availability and to support clinical continuity.

Key competitive dynamics and capability differentiators that determine which compounding providers secure trust, scale, and clinical partnerships in specialized therapeutic areas

The competitive landscape is populated by specialized compounding pharmacies, hospital-based compounding units, and contract development and manufacturing organizations that offer compounded and bespoke dosage options. Leading players demonstrate a combination of stringent quality systems, validated sterility assurance processes, and partnerships with clinical networks to secure formulary placements. These organizations often invest in robust analytical laboratories, continuous staff training programs, and electronic batch record systems to support traceability and inspection readiness. In addition to in-house capabilities, many firms leverage strategic alliances with clinical specialists and academic centers to drive product innovation, validate niche formulations, and build clinical evidence for off-label or complex-use preparations.

Differentiation arises through scale of operations, depth of therapeutic expertise, and agility in distribution. Organizations that can offer rapid turnaround without compromising quality tend to secure preferred relationships with outpatient clinics, home healthcare providers, and certain hospital pharmacies. Meanwhile, contract manufacturing partners that can accommodate small-batch sterile production while maintaining high compliance standards are attractive to healthcare systems requiring oncology support or specialized injectable formulations. Investment patterns emphasize automation for dose accuracy, environmental monitoring advancements, and robust supply chain governance to ensure consistent input quality. Competitive strategies increasingly incorporate digital ordering platforms and clinical consultation services to deepen customer engagement and to improve adherence to prescribing and administration protocols.

Practical and prioritized actions for compounding pharmacy executives to enhance compliance, supply resilience, clinical partnerships, and scalable manufacturing capabilities

Industry leaders should adopt a prioritized set of actions to strengthen resilience, demonstrate compliance, and capture clinical partnerships. First, invest in quality management systems that extend beyond baseline regulatory requirements to include comprehensive environmental monitoring, validated cleaning procedures, and routine third-party audits to reinforce inspection readiness. Second, diversify supplier networks and implement dual-sourcing or nearshoring strategies for critical active ingredients and sterile components to reduce exposure to trade policy shifts and logistic disruptions. Third, build modular facility capacity that allows for flexible scaling between non-sterile and sterile production while preserving segregation and contamination controls. Fourth, deepen clinical engagement by establishing collaborative pathways with prescribers and hospital formulary committees to document clinical outcomes and to accelerate acceptance of compounded therapies. Fifth, modernize commercial channels by integrating digital ordering, secure prescription verification, and tailored distribution services for inpatient, outpatient, and veterinary customers.

Finally, embed a forward-looking talent strategy that prioritizes sterile processing expertise, regulatory affairs competence, and supply chain analytics. These initiatives should be sequenced with clear governance and measurable milestones so that capital allocation aligns with the most urgent operational gaps and the areas of highest clinical impact. Collectively, this set of actions positions compounding organizations to balance regulatory compliance, clinical relevance, and operational efficiency.

Research methodology combining regulatory review, expert practitioner interviews, and comparative operational assessments to produce actionable and verifiable strategic guidance

This analysis synthesizes publicly available regulatory guidance, industry technical literature, expert interviews with quality and operations leaders, and operational best practices observed across hospital and commercial compounding providers. The research approach combined systematic review of pharmacopoeial standards and state-level regulatory frameworks with direct consultations to validate operational implications and to surface real-world mitigation strategies. Where appropriate, comparative facility assessments informed recommendations on cleanroom classification, sterility testing regimens, and environmental monitoring frequency. Supplier and distribution analyses were triangulated through procurement leader interviews and logistics performance indicators to assess lead time variability and contingency planning practices.

Triangulation of sources and cross-validation with subject matter experts ensured that the findings emphasize practical, implementable guidance rather than speculative scenarios. The methodology prioritized actionable intelligence by focusing on operational feasibility, regulatory alignment, and clinical adoption pathways. Limitations include the inherent variability of state and national regulations and the dynamic nature of trade policy; therefore, the research emphasizes adaptable strategies and continuous monitoring. Overall, the methodology supports robust insights grounded in operational realities and regulatory precedents.

A strategic synthesis emphasizing the imperative for quality-first operations, supply resilience, and clinical collaboration to secure long-term viability and patient access

Compounding pharmacies stand at a pivotal juncture where clinical demand for personalized therapies intersects with increased scrutiny and more complex supply chains. The industry's future will favor providers that combine rigorous quality systems, flexible manufacturing platforms, and deep clinical engagement. Regulatory evolution and tariff dynamics require a proactive posture toward supplier diversification, near-term inventory planning, and investment in validated sterile processing capabilities. Technological adoption-ranging from automated compounding systems to digital prescription verification-can bolster accuracy, throughput, and compliance, but must be paired with sustained workforce training and governance.

Decision-makers should prioritize initiatives that deliver immediate compliance gains and measurable improvements in service reliability while planning phased investments to broaden sterile and ophthalmic capabilities. By aligning operational resilience with clear clinical value propositions, compounding pharmacies can reinforce their role in personalized care pathways and capture sustainable demand across human and veterinary segments. The concluding perspective emphasizes that deliberate, data-informed investment and collaborative clinical partnerships are central to long-term viability and to preserving patient access to vital customized therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing reliance on sterile compounding for personalized oncology therapies with advanced safety measures
  • 5.2. Rising demand for hormone replacement therapy compounding solutions tailored to individual patient hormone profiles
  • 5.3. Implementation of robotic automation and quality control technologies in high-volume compounding pharmacies to minimize human error
  • 5.4. Expansion of telemedicine integration driving remote prescription fulfillment and home delivery for compounded medications
  • 5.5. Growth of veterinary compounding services offering specialized formulations for exotic and small animal care
  • 5.6. Regulatory scrutiny intensifying after high-profile compounding facility inspections leading to compliance upgrades
  • 5.7. Adoption of blockchain tracking systems for end-to-end transparency in compounding ingredients and distribution channels
  • 5.8. Increased collaboration between hospital pharmacies and independent compounding labs to address drug shortages efficiently
  • 5.9. Implementation of AI-driven prescription validation and dosage optimization platforms within compounding workflows for improved accuracy and throughput
  • 5.10. Development of green compounding pharmacies adopting solvent recycling and biodegradable packaging to minimize environmental impact

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Compounding Pharmacies Market, by Type

  • 8.1. Non-Sterile
    • 8.1.1. Oral
      • 8.1.1.1. Capsules
      • 8.1.1.2. Powder
      • 8.1.1.3. Solutions & Suspensions
      • 8.1.1.4. Syrups
      • 8.1.1.5. Tablets
    • 8.1.2. Topical
      • 8.1.2.1. Creams
      • 8.1.2.2. Gels
      • 8.1.2.3. Lotions
      • 8.1.2.4. Ointments
  • 8.2. Sterile
    • 8.2.1. Injectable
      • 8.2.1.1. Intramuscular
      • 8.2.1.2. Intravenous
      • 8.2.1.3. Subcutaneous
    • 8.2.2. Ophthalmic
      • 8.2.2.1. Drops
      • 8.2.2.2. Ointments

9. Compounding Pharmacies Market, by Application

  • 9.1. Dermatology
    • 9.1.1. Acne
    • 9.1.2. Eczema
    • 9.1.3. Psoriasis
  • 9.2. Hormone Replacement Therapy
    • 9.2.1. Estrogen
    • 9.2.2. Testosterone
    • 9.2.3. Thyroid
  • 9.3. Oncology
  • 9.4. Pain Management
    • 9.4.1. Non Opioid
    • 9.4.2. Opioid
  • 9.5. Veterinary
    • 9.5.1. Large Animal
    • 9.5.2. Small Animal

10. Compounding Pharmacies Market, by Use-Case

  • 10.1. Human
    • 10.1.1. Inpatient
    • 10.1.2. Outpatient
  • 10.2. Veterinary
    • 10.2.1. Large Animals
    • 10.2.2. Small Animals

11. Compounding Pharmacies Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Hospital Pharmacies
  • 11.3. Online Pharmacies

12. Compounding Pharmacies Market, by End User

  • 12.1. Academic & Research Institutes
  • 12.2. Clinics
  • 12.3. Home Healthcare
  • 12.4. Hospital Pharmacies
  • 12.5. Retail Pharmacies

13. Compounding Pharmacies Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Compounding Pharmacies Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Compounding Pharmacies Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Fagron NV
    • 16.3.2. Fresenius Kabi AG
    • 16.3.3. PharMEDium (AmerisourceBergen Corporation)
    • 16.3.4. B. Braun Medical Inc.
    • 16.3.5. Ascend Clinical LLC
    • 16.3.6. Medisca Inc.
    • 16.3.7. Empower Pharmacy, Inc.
    • 16.3.8. Wedgewood Village Pharmacy, LLC
    • 16.3.9. Pencol Compounding Pharmacy Ltd.
    • 16.3.10. Professional Compounding Centers of America, LLC
    • 16.3.11. Diplomat Pharmacy, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY USE-CASE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY USE-CASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS COMPOUNDING PHARMACIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COMPOUNDING PHARMACIES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. COMPOUNDING PHARMACIES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. COMPOUNDING PHARMACIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPOUNDING PHARMACIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON-STERILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY POWDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SOLUTIONS & SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SYRUPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LOTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY STERILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPHTHALMIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ECZEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ESTROGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY TESTOSTERONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY NON OPIOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OPIOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY USE-CASE, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY USE-CASE, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY VETERINARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY LARGE ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY SMALL ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 306. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 307. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 310. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 316. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 317. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL COMPOUNDING PHARMACIES MARKET SIZE, BY HOME HEALT